Abstract
Objective: To determine the efficacy and safety of empagliflozin in combination with metformin compared to empagliflozin in combination with linagliptin in patients with Type 2 Diabetes Mellitus (T2DM).
Methodology: This analytical study was carried out at National Medical Centre (NMC) Hospital, Karachi, Pakistan, from 20 November 2022 till 20 February 2023. Two treatment groups were compared: Group A received empagliflozin 12.5 mg with metformin 500 mg OD and Group B received empagliflozin 10 mg with linagliptin 5 mg OD daily given for 12 weeks. The primary outcomes were body mass index (BMI), waist Circumference (WC), waist to hip ratio (WHR) and assessing glycated hemoglobin (HgA1c), fasting blood glucose level (FBS) and Random blood sugar (RBS). The secondary outcomes were lipid profiles, liver enzymes, pancreatic enzymes, and renal functions tests along with urinalysis. The statistical analysis was performed using SPSS 23.
Result: By the end of 12th week, the difference between Group A and Group B was statistically significant with lower mean BMI, WC and WHR of Group A (p<0.05). Supplementary, glycemic control was significantly better in Group B and safety profile showed no variations between the groups.
Conclusion: There was a notable significant difference in body weight loss with empagliflozin-metformin combination therapy having greater effect than the empagliflozin-linagliptin combination in T2DM patients.

Key words: Diabetes Mellitus, SGLT 2 Inhibitors, metformin, DPP4 Inhibitors, obesity, weight loss.